A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Intratumoral stimulatory dendritic cells (SDCs) are crucial for anti-cancer immune responses by activating cytotoxic T cells.
• Understanding SDC regulation in the tumor microenvironment (TME) is key for developing novel cancer therapies.

Purpose of the Study:

• To investigate the mechanisms regulating SDC abundance in the TME.
• To explore the role of natural killer (NK) cells and FLT3 ligand (FLT3L) in SDC regulation and their impact on immunotherapy response.

Main Methods:

• Analysis of SDC abundance in human melanoma and its association with FLT3LG gene expression.
• Investigating FLT3L production by lymphocytes, particularly NK cells.
• Utilizing genetic and cellular ablation models in mice to assess NK cell function in SDC regulation.
• Correlating NK cell frequency with SDC presence, anti-PD-1 immunotherapy response, and patient survival in human cancers.

Main Results:

• SDC abundance in human melanoma correlates with intratumoral FLT3LG expression.
• Lymphocytes, especially NK cells, are the primary producers of FLT3L in tumors.
• NK cells form stable conjugates with SDCs in the TME and are essential for maintaining SDC abundance via FLT3L production.
• NK cell frequency is linked to SDC presence, patient responsiveness to anti-PD-1 immunotherapy, and improved overall survival.

Conclusions:

• The axis of innate immune SDCs and NK cells serves as a prognostic indicator for T cell-directed immunotherapy.
• These innate immune cells are vital for enhancing T cell-mediated anti-tumor responses.
• Targeting the SDC-NK cell axis presents a promising strategy for novel cancer therapies.